Citigroup Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) Stock

Insulet (NASDAQ:PODD) had its price objective boosted by equities researchers at Citigroup from $150.00 to $170.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. Citigroup‘s price target points to a potential upside of 16.03% from the stock’s previous close.

A number of other analysts have also recently weighed in on PODD. JPMorgan Chase & Co. cut shares of Insulet from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $275.00 to $152.00 in a research note on Thursday, August 6th. UBS Group lowered their price objective on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Barclays raised shares of Insulet to a “hold” rating in a report on Wednesday, October 7th. BTIG Research cut shares of Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $200.00 price objective on shares of Insulet in a report on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Insulet has an average rating of “Hold” and a consensus price target of $185.38.

Insulet Price Performance

Shares of PODD traded down $9.61 during midday trading on Thursday, hitting $146.51. The company’s stock had a trading volume of 1,567,721 shares, compared to its average volume of 1,380,594. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. Insulet has a one year low of $126.40 and a one year high of $354.88. The stock has a market capitalization of $10.16 billion, a price-to-earnings ratio of 23.86, a price-to-earnings-growth ratio of 1.21 and a beta of 1.06. The company’s fifty day simple moving average is $141.97 and its two-hundred day simple moving average is $176.65.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The business had revenue of $842.00 million for the quarter, compared to analyst estimates of $832.63 million. During the same period last year, the firm posted $1.24 earnings per share. Insulet’s revenue was up 19.2% compared to the same quarter last year. As a group, equities analysts expect that Insulet will post 6.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insulet

A number of institutional investors have recently modified their holdings of PODD. BlackRock Inc. bought a new position in Insulet during the second quarter worth $1,018,582,000. Arrowstreet Capital Limited Partnership lifted its holdings in Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after buying an additional 1,011,369 shares during the period. Man Group plc acquired a new position in Insulet in the second quarter valued at $78,746,000. Bank of America Corp DE bought a new stake in Insulet during the second quarter valued at $64,921,000. Finally, Bank of New York Mellon Corp bought a new stake in Insulet during the second quarter valued at $60,615,000.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.